Semaglutide showdown: Pills or shots—Which is right for you?

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Novo, Eli Lilly oral obesity drugs included in new FDA priority voucher program

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read ...

Diabetes meds for weight loss, explained by the pros

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...
MarketWatch

FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity

-- Novo Nordisk hopes to expand Wegovy(R) label by becoming the first GLP-1 treatment for obesity in a pill -- The FDA filing is based on the results of the phase 3 OASIS 4 trial that evaluated oral ...
Medical Dialogues

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

This came after the drug major Sun Pharma Laboratories presented the proposal to conduct Phase III clinical trial titled “A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, ...
Morningstar

BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...
Medscape

GLP-1 Agonists Linked to Anorgasmia in a 71-Year-Old Woman

Clinicians prescribing GLP-1 agents should ask about sexual function and consider medication review if new anorgasmia appears.
Morningstar

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared ...